Tocilizumab in the Treatment of Eosinophilic Fasciitis: A Case Study and Review of Literature

Mediterr J Rheumatol. 2023 Mar 31;34(1):78-85. doi: 10.31138/mjr.34.1.78. eCollection 2023 Mar.

Abstract

Eosinophilic fasciitis (EF) is a rare connective-tissue disorder that is characterised by subacute onset of erythema, oedema, and induration of the skin and soft tissues of the limbs and trunk. Although several triggers have been hypothesised to be associated with EF, the aetiology of eosinophilic fasciitis (EF) is still unclear, and several treatment regimens have been proposed to treat this disease. In this article, we report a case of a 72-year-old gentleman with multiple comorbidities who presented to the clinic for diffuse skin thickening present on his forearms, thighs, legs bilaterally, and over the pelvis. The patient was diagnosed with EF and failed multiple treatment regimens including prednisone, methotrexate, rituximab, but finally responded and was maintained on tocilizumab. In this article, we will review the current understanding of EF, diagnostic approach, popular treatments and review other cases of EF in which tocilizumab was used.

Keywords: Shulman’s disease; eosinophilic fasciitis; tocilizumab.

Publication types

  • Review